Age and CD4 + T cell count influence ESAT6-CFP10 skin test results in patients with tuberculosis-Reference-Cited by-同舟云学术

Age and CD4 + T cell count influence ESAT6-CFP10 skin test results in patients with tuberculosis

Published:2024-04-19 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

yuanyuan 袁媛¹,Liu Xuhui²,Xia Lu³,Wu Qiaoyu⁴,Liu Xiangxiang²,Huang Huan³,Lu Shuihua²

Affiliation:

1. Tongji University

2. The Third People’s Hospital of Shenzhen, University of Science and Technology

3. Fudan University

4. Bengbu Medical College

Abstract

Background Cellular immunity plays an important role in the pathogenesis and diagnosis of tuberculosis. The ESAT6-CFP10 skin test has good sensitivity and specificity. Levels of CD4 + T lymphocytes may influence the results of the ESAT6-CFP10 skin test in TB patients. Methods ESAT6-CFP10 skin tests were conducted on 271 admitted patients at Shanghai Public Health Clinical Center. TB patients were divided into either positive or negative EC skin test groups for retrospective analysis with CD4 + T lymphocyte counts to explore the relationship between CD4 + T lymphocyte mediated cellular immunity and ESAT6-CFP10 skin test results. A total of 271 patients with TB were included in the study. Results Among TB patients, 157 cases were EC positive and 114 cases were EC negative. Univariate analysis of age, gender, BMI, CD4+, CD 8+, CD4+/CD8 + showed that age and CD4 + T lymphocytes were significantly associated with EC skin test results (p < 0.05). Binary Logistic regression analysis of EC skin test results showed that age and CD4 + were the influencing factors of EC skin test (p < 0.05). AUC (95% CI) for age and CD4 + were 0.389 (0.322–0.456) and 0.623 (0.555–0.691), respectively. Conclusion Age and CD4 + T lymphocytes affect the results of ESAT6-CFP10 skin test in patients with tuberculosis, but more data are needed to support whether they can be used as auxiliary indicators to predict the results of EC skin test.

Publisher

Research Square Platform LLC

Reference27 articles.

1. 1. Global tuberculosis report 2022. Geneva: World Health Organization; 2022.

2. 2. Li F, Xu M, Zhou L, Xiong Y, Xia L, Fan X, et al. Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial. Clin Vaccine Immunol. 2016;23(9):767 − 73.

3. 3. Li F, Xu M, Qin C, Xia L, Xiong Y, Xi X, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect. 2016;22(10):889 e9- e16.

4. 4. Xu M, Lu W, Li T, Li J, Du W, Wu Q, et al. Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials. Clin Infect Dis. 2022;74(4):668 − 77.

5. 5. Xia L, Xu M, Li F, Li T, Yang H, Wang W, et al. High Accuracy of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for the Detection of Tuberculosis Infection: A Phase III, Multi-centered, Double-blind, Hospital-based, Randomized Controlled Trial. Int J Infect Dis. 2022.